Taysha Gene Therapies (TSHA) Tops Q3 EPS by 19c

Taysha Gene Therapies (NASDAQ: TSHA) reported Q3 EPS of ($0.64), $0.19 better than the analyst estimate of ($0.83).

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.

You May Also Be Interested In

• Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
• Alcoa prices $2.6B in senior notes to fund South32 asset deal
• Signet Jewelers (SIG) Tops Q2 EPS by 47c, Misses on Revenue; Offers FY27 Guidance